STIM — Neuronetics Income Statement
0.000.00%
Last trade - 00:00
- $22.15m
- $39.26m
- $71.35m
- 30
- 65
- 12
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 62.7 | 49.2 | 55.3 | 65.2 | 71.3 |
Cost of Revenue | |||||
Gross Profit | 47.3 | 37.7 | 43.7 | 49.7 | 51.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 89.6 | 72.5 | 82.9 | 100 | 102 |
Operating Profit | -26.9 | -23.2 | -27.6 | -35.1 | -30.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -29 | -27.5 | -31.2 | -37.2 | -30.2 |
Net Income After Taxes | -29 | -27.5 | -31.2 | -37.2 | -30.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -29 | -27.5 | -31.2 | -37.2 | -30.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -29 | -27.5 | -31.2 | -37.2 | -30.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.58 | -1.41 | -1.17 | -1.36 | -1.05 |